BridgeBio Pharma, Inc. (BBIO) financials: revenue, earnings and cash flow
Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$725M, a net margin of -144.4%; the best year in this period was 2017 with -$31M.
Over the twelve months to September 30, 2026, revenue was $946M and net income -$592M.
Free cash flow was -$447M in fiscal 2025 and positive in 0 of the 9 years shown.
The diluted share count rose 526% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $946M | $502M | $222M | $9M | $78M | $70M | $8M | $41M | — | — |
| Gross profit | $892M | $481M | $218M | $7M | $74M | $67M | — | — | — | — |
| Operating income | -$364M | -$523M | -$593M | -$607M | -$512M | -$577M | -$474M | -$266M | -$184M | -$44M |
| Net income | -$592M | -$725M | -$536M | -$643M | -$481M | -$563M | -$449M | -$261M | -$131M | -$31M |
| EPS (diluted) | $-3.03 | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 | $-3.80 | $-2.48 | $-2.12 | $-1.00 |
| R&D | $536M | $452M | $506M | $456M | $399M | $451M | $337M | $210M | $140M | $31M |
| Revenue growth | — | +126.3% | +2285.3% | −88.0% | +11.4% | +745.1% | −79.7% | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$369M | -$446M | -$521M | -$528M | -$419M | -$498M | -$400M | -$254M | -$137M | -$40M |
| Capital spending | -$835000 | -$1M | -$933000 | -$1M | -$5M | -$13M | -$8M | -$3M | -$2M | -$464000 |
| Free cash flow | -$370M | -$447M | -$522M | -$529M | -$424M | -$511M | -$407M | -$256M | -$139M | -$41M |
| Dividends paid | — | — | — | — | — | — | — | $997000 | — | $1M |
| Buybacks | $253M | $48M | $0 | $0 | $0 | $200M | $75M | — | — | — |
| Stock-based pay | $152M | $133M | $96M | $109M | $92M | $100M | $58M | $21M | $6M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $587M | $681M | $376M | $428M | $788M | $607M | $546M | $436M | $92M |
| Debt | — | $2.0B | $447M | $460M | $447M | $453M | $112M | $103M | $55M | — |
| Equity | — | -$2.1B | -$1.5B | -$1.4B | -$1.3B | -$870M | $58M | $408M | $315M | $86M |
| Total assets | — | $936M | $919M | $546M | $623M | $1.0B | $704M | $632M | $465M | — |
| Shares (diluted) | 196M | 192M | 186M | 163M | 147M | 144M | 118M | 105M | 62M | 31M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 94.3% | 95.8% | 98.2% | 73.7% | 95.6% | 95.5% | — | — | — | — |
| Operating margin | -38.5% | -104.2% | -267.2% | -6528.7% | -659.6% | -827.1% | -5752.0% | -656.4% | — | — |
| Net margin | -62.6% | -144.4% | -241.4% | -6913.9% | -619.7% | -806.9% | -5439.7% | -642.5% | — | — |
| FCF margin | -39.1% | -89.0% | -235.1% | -5686.6% | -546.5% | -733.2% | -4936.7% | -631.7% | — | — |
| ROIC | — | — | — | — | — | — | -220.2% | -41.1% | -39.3% | -40.4% |
| ROE | — | 34.7% | 36.5% | 47.5% | 38.4% | 64.6% | -774.9% | -63.8% | -41.5% | -35.6% |
Frequently asked questions
What is BridgeBio Pharma’s annual revenue?
$502M in fiscal 2025 and $946M over the twelve months to September 30, 2026.
How much profit does BridgeBio Pharma make?
Net income was -$725M in fiscal 2025 (net margin -144.4%).
Is BridgeBio Pharma’s revenue growing?
Yes: revenue rose 126.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.